{"id":517935,"date":"2021-07-27T07:03:18","date_gmt":"2021-07-27T11:03:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\/"},"modified":"2021-07-27T07:03:18","modified_gmt":"2021-07-27T11:03:18","slug":"matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\/","title":{"rendered":"Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2021 Financial and Operational Results on August 10, 2021"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">BEDMINSTER, N.J., July  27, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QoEmBgdJ0aRbwhNyiDhy9BhBVMr0JddeiB0qsILCRa6BTcz82F3lcDdlYI1d2BjPN1PYrc42ZsMFKpY1s4sZ2Ut1J1V24towQzGWfTAOuv5krcGlUW4UKL5fPc4W4oeH\" rel=\"nofollow noopener\" target=\"_blank\">Matinas BioPharma Holdings, Inc.<\/a> (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company\u00a0focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) delivery platform, today announced that the Company will host a conference call and live audio webcast on Tuesday, August 10, 2021 at 8:00 a.m. ET to discuss operational and financial results for the second quarter ended June 30, 2021.<\/p>\n<p align=\"justify\">To participate in the call, please dial (877) 407-5976 (Toll-Free) or (412) 902-0031 (Toll) and reference conference ID 13720567. The live webcast will be accessible on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M1RxHzYPxoWlvQywGLw0WAOzUKMh3zcKDeea0lR3PS2oGy1hQATQ0Qimny11gZJ2FB1yoj-Flj4-SDYZbvRUfHcUpz70luzqG1X4ZL7L7Dg=\" rel=\"nofollow noopener\" target=\"_blank\">Investors<\/a>\u00a0section of Matinas\u2019 website, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rm3lY9v4Oyl-Lw7Q1-HUmGZPjv8BnrcnOmxmMrpnXSvnRcchI6k-9IERqPROiPMEXDOCZqXvoehzyVWJ0ZddagL7rkvZ-e_TYF263s8U5t0=\" rel=\"nofollow noopener\" target=\"_blank\">www.matinasbiopharma.com<\/a>, and archived for 90 days.<\/p>\n<p align=\"justify\">\n        <strong>About Matinas BioPharma<\/strong>\n      <\/p>\n<p align=\"justify\">Matinas BioPharma is a biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) delivery platform. The Company is developing its own internal portfolio of products as well as partnering with leading pharmaceutical companies to develop new formulations that take full advantage of the unique characteristics of the LNC platform. \u00a0\u00a0<\/p>\n<p align=\"justify\">Preclinical and clinical data have demonstrated that this novel technology can provide solutions to many of the complex challenges in achieving safe and effective intracellular delivery, for both small molecules and larger, more complex molecules, such as mRNA, DNA plasmids, antisense oligonucleotides and vaccines.\u00a0\u00a0 The combination of a unique mechanism of action and flexibility in both the formulation and route of administration (including oral), position Matinas\u2019 LNC technology to potentially become the preferred next-generation intracellular drug delivery vehicle and an important improvement over both lipid nanoparticles and viral vectors.<\/p>\n<p align=\"justify\">MAT2203 is an oral, LNC formulation of the highly effective, but also highly toxic, antifungal medicine amphotericin B, primarily used as a first-line treatment for invasive fungal infections. MAT2203 is currently in a Phase 2 open-label, sequential cohort study (EnACT) in HIV-infected patients with cryptococcal meningitis. EnACT is nearing the completion of enrollment of its second cohort of patients, with the next DSMB evaluation of safety and efficacy data anticipated to occur in the third quarter of 2021.<\/p>\n<p align=\"justify\">MAT2501 is an oral, LNC formulation of the broad-spectrum aminoglycoside antibiotic amikacin, primarily used to treat chronic and acute bacterial infections. With the support of the Cystic Fibrosis Foundation, MAT2501 is currently undergoing important preclinical studies and expects to enter a Phase 1 human clinical trial later in 2021. MAT2501 would be the first and only oral aminoglycoside and is being positioned with an initial indication for the treatment of nontuberculous mycobacterial (NTM) lung disease, including infections in patients with cystic fibrosis (CF).<\/p>\n<p align=\"justify\">LYPDISO\u2122, is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, intended for the treatment of cardiovascular and metabolic conditions. This next-generation omega-3 therapy has been shown in two head-to-head studies to provide effective triglyceride-lowering and significantly higher EPA blood levels than Vascepa<sup>\u00ae<\/sup>. The Company has initiated a process to identity and secure a potential partner to continue development of LYPDISO.\u00a0<\/p>\n<p align=\"justify\">\n        <strong>Forward Looking Statements<\/strong>:<\/p>\n<p align=\"justify\">This release contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the LNC platform delivery technology, the Company\u2019s strategic focus and the future development of its product candidates, including MAT2203, MAT2501 and LYPDISO, the anticipated timing of regulatory submissions, the anticipated timing of clinical studies, the anticipated timing of regulatory interactions, the Company\u2019s ability to identify and pursue development and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;could,&#8221; &#8220;believes,&#8221; &#8220;estimates&#8221; and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company\u2019s intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company\u2019s products; and the other factors listed under &#8220;Risk Factors&#8221; in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma\u2019s product candidates are all in a development stage and are not available for sale or use.<\/p>\n<p align=\"justify\">\n        <strong>Investor and Media Contact<\/strong>\n      <\/p>\n<p align=\"justify\">Peter Vozzo<br \/>Westwicke\/ICR<br \/>443-213-0505<br \/>peter.vozzo@westwicke.com<\/p>\n<p align=\"justify\">Source: Matinas BioPharma Holdings, Inc.<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NzAyNyM0MzE1NjA0IzIwMjM2MTg=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/75a917fe-71b0-4cc0-8efe-46f9fe4aae2e\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BEDMINSTER, N.J., July 27, 2021 (GLOBE NEWSWIRE) &#8212; Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company\u00a0focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) delivery platform, today announced that the Company will host a conference call and live audio webcast on Tuesday, August 10, 2021 at 8:00 a.m. ET to discuss operational and financial results for the second quarter ended June 30, 2021. To participate in the call, please dial (877) 407-5976 (Toll-Free) or (412) 902-0031 (Toll) and reference conference ID 13720567. The live webcast will be accessible on the Investors\u00a0section of Matinas\u2019 website, www.matinasbiopharma.com, and archived for 90 days. About Matinas BioPharma Matinas BioPharma is a biopharmaceutical company focused on &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2021 Financial and Operational Results on August 10, 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-517935","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2021 Financial and Operational Results on August 10, 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2021 Financial and Operational Results on August 10, 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BEDMINSTER, N.J., July 27, 2021 (GLOBE NEWSWIRE) &#8212; Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company\u00a0focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) delivery platform, today announced that the Company will host a conference call and live audio webcast on Tuesday, August 10, 2021 at 8:00 a.m. ET to discuss operational and financial results for the second quarter ended June 30, 2021. To participate in the call, please dial (877) 407-5976 (Toll-Free) or (412) 902-0031 (Toll) and reference conference ID 13720567. The live webcast will be accessible on the Investors\u00a0section of Matinas\u2019 website, www.matinasbiopharma.com, and archived for 90 days. About Matinas BioPharma Matinas BioPharma is a biopharmaceutical company focused on &hellip; Continue reading &quot;Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2021 Financial and Operational Results on August 10, 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-27T11:03:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NzAyNyM0MzE1NjA0IzIwMjM2MTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2021 Financial and Operational Results on August 10, 2021\",\"datePublished\":\"2021-07-27T11:03:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\\\/\"},\"wordCount\":902,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NzAyNyM0MzE1NjA0IzIwMjM2MTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\\\/\",\"name\":\"Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2021 Financial and Operational Results on August 10, 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NzAyNyM0MzE1NjA0IzIwMjM2MTg=\",\"datePublished\":\"2021-07-27T11:03:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NzAyNyM0MzE1NjA0IzIwMjM2MTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NzAyNyM0MzE1NjA0IzIwMjM2MTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2021 Financial and Operational Results on August 10, 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2021 Financial and Operational Results on August 10, 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\/","og_locale":"en_US","og_type":"article","og_title":"Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2021 Financial and Operational Results on August 10, 2021 - Market Newsdesk","og_description":"BEDMINSTER, N.J., July 27, 2021 (GLOBE NEWSWIRE) &#8212; Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company\u00a0focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) delivery platform, today announced that the Company will host a conference call and live audio webcast on Tuesday, August 10, 2021 at 8:00 a.m. ET to discuss operational and financial results for the second quarter ended June 30, 2021. To participate in the call, please dial (877) 407-5976 (Toll-Free) or (412) 902-0031 (Toll) and reference conference ID 13720567. The live webcast will be accessible on the Investors\u00a0section of Matinas\u2019 website, www.matinasbiopharma.com, and archived for 90 days. About Matinas BioPharma Matinas BioPharma is a biopharmaceutical company focused on &hellip; Continue reading \"Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2021 Financial and Operational Results on August 10, 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-27T11:03:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NzAyNyM0MzE1NjA0IzIwMjM2MTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2021 Financial and Operational Results on August 10, 2021","datePublished":"2021-07-27T11:03:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\/"},"wordCount":902,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NzAyNyM0MzE1NjA0IzIwMjM2MTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\/","name":"Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2021 Financial and Operational Results on August 10, 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NzAyNyM0MzE1NjA0IzIwMjM2MTg=","datePublished":"2021-07-27T11:03:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NzAyNyM0MzE1NjA0IzIwMjM2MTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NzAyNyM0MzE1NjA0IzIwMjM2MTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-second-quarter-2021-financial-and-operational-results-on-august-10-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2021 Financial and Operational Results on August 10, 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/517935","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=517935"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/517935\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=517935"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=517935"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=517935"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}